Bevacizumab and cyclosphosphamide, doxorubicin, vincristine and prednisone in combination for patients with peripheral T-cell or natural killer cell neoplasms: An Eastern Cooperative Oncology Group study (E2404)

Leukemia and Lymphoma

Volumn 55, Issue 4, 2014, Pages 768-772

  Ganjoo, Kristen ^a   Hong, Fangxin ^b   Horning, Sandra J ^c   Gascoyne, Randy D ^d   Natkunam, Yasodha ^a   Swinnen, Lode J ^e   Habermann, Thomas M ^f   Kahl, Brad S ^g   Advani, Ranjana H ^a  

^a STANFORD UNIVERSITY   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c GENENTECH INC   (United States)

^d BRITISH COLUMBIA CANCER AGENCY   (Canada)

^e JOHNS HOPKINS UNIVERSITY   (United States)

^f MAYO CLINIC   (United States)

^g UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

Chemotherapeutic approaches; Immunotherapeutic approaches; Lymphoma and Hodgkin disease

Indexed keywords

BEVACIZUMAB; CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; VINCRISTINE; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADULT; AGED; ANEMIA; ARTICLE; CANCER GROWTH; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL ARTICLE; COLON PERFORATION; CONGESTIVE HEART FAILURE; DIGESTIVE SYSTEM PERFORATION; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HEART VENTRICLE ARRHYTHMIA; HUMAN; HYPERTENSION; INFECTION; MAINTENANCE DRUG DOSE; MALE; MULTIPLE CYCLE TREATMENT; NK T CELL LYMPHOMA; OVERALL SURVIVAL; PERIPHERAL T CELL LYMPHOMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RESTRICTIVE CARDIOMYOPATHY; THROMBOCYTOPENIA; TREATMENT RESPONSE; VEIN THROMBOSIS; VERY ELDERLY; CANCER STAGING; LYMPHOMA, T-CELL, PERIPHERAL; MIDDLE AGED; MORTALITY; NATURAL KILLER CELL; PATHOLOGY; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BEVACIZUMAB; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; HUMANS; KILLER CELLS, NATURAL; LYMPHOMA, T-CELL, PERIPHERAL; MALE; MIDDLE AGED; NEOPLASM STAGING; PREDNISONE; TREATMENT OUTCOME; VINCRISTINE; YOUNG ADULT;

EID: 84904318140     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2013.816700     Document Type: Article

References (37)

1. Savage KJ, Chhanbhai M, Gascoyne RD, et al. Characterization of peripheral T cell lymphomas in a single North American institution by the WHO classification. Ann Oncol 2004;15:1467-1475. (Pubitemid 39409735)
2. Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: International Agency for Research on Cancer; 2008.
3. Armitage JO. The aggressive peripheral T-cell lymphomas: 2012 update on diagnosis, risk stratification, and management. Am J Hematol 2012;87:511-519.
4. Bertolini F, Paolucci M, Peccatori F, et al. Angiogenic growth factors and endostatin in non-Hodgkin's lymphoma.Br J Haematol 1999; 106: 504-509. (Pubitemid 29450678)
5. Salven P, Orpana A, Teerenhovi L, et al. Simultaneous elevation in the serum concentration of the angiogenic growth factors and bFGF is an independent predictor of poor prognosis in patients with non- Hodgkin's lymphoma: a single institution study of 200 patients. Blood 2000;96:3712-3718.
6. Gratzinger D, Zhao S, Tibshirani RJ, et al. Prognostic significance of VEGF, VEGF receptors, and microvessel density in diffuse large B cell lymphoma treated with anthracycline-based chemotherapy. Lab Invest 2008; 88: 38-47.
7. Rafii S, Lyden D, Benezra R, et al. Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy? Nat Rev Cancer 2002; 2: 826-835.
8. Shipp MA, Ross KN, Tamayo P, et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med 2002; 8: 68-74 (Pubitemid 34101731)
9. Kuramoto K, Sakai A, Shigemasa K, et al. High expression of MCL1 gene related to vascular endothelial growth factor is associated with poor outcome in non-Hodgkin's lymphoma. Br J Haematol 2002; 116: 158-161. (Pubitemid 34122074)
10. Lenz G, Wright G, DaveSS, et al.;Lymphoma/LeukemiaMolecular Profiling Project. Stromal gene signatures in B cell lymphomas. N Engl J Med 2008; 359: 2313-2323.
11. Zhao WL, Mourah S, Mounier N, et al. Vascular endothelial growth factor-A is expressed both on lymphoma cells and endothelial cell in angioimmunoblastic T-cell lymphoma and related to lymphoma progression. Lab Invest 2004;84:1512-1519. (Pubitemid 39482168)
12. Zhang W, Wang L, Zhou D, et al. Expression of tumor-associated macrophages and vascular endothelial growth factor correlates with poor prognosis of peripheral T-cell lymphoma, not otherwise specified. Leuk Lymphoma 2011; 52: 46-52.
13. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizmab plus irinotecan, fluoracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-2342. (Pubitemid 38702844)
14. Sandler A, Gray R, Perry MC, et al. Palitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355: 2542-2550. (Pubitemid 44917502)
15. ChesonBD, Horning SJ, CoiffierB, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999; 17: 1244.
16. Advani RH, Hong F, Horning SJ, et al. Cardiac toxicity associated with bevacizumab (Avastin) in combination with CHOP chemotherapy for peripheral T cell lymphoma in ECOG 2404 trial. Leuk Lymphoma 2012; 53: 718-720.
17. de Leval L, Rickman DS, Thielen C, et al. The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T (TFH) cells. Blood 2007;109:4952-4963. (Pubitemid 46827794)
18. Ganjoo KN, An CS, Robertson MJ, et al. Rituximab, bevacizumab and CHOP (RE-CHOP) in untreated diffuse large B-cell lymphoma: safety, biomarker and pharmacokinetic analysis. Leuk Lymphoma 2006; 47: 998-1005.
19. Stopeck AT, Unger JM, Rimsza LM, et al. Aphase II trial of standard dose cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) and rituximab plus bevacizumab for patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: SWOG 0515. Blood 2012; 120: 1210-1217.
20. Seymour JF, Pfreundshuh M, Coiffier B, et al. The addition of bevacizumab to standard therapy with R-CHOP in patients with previously untreated diffuse large B-cell lymphoma is associated with an increased rate of cardiac adverse events: final analysis of safety and efficacy outcomes from the placebo-controlled phase 3 MAIN study. Blood 2012;120(Suppl. 1): Abstract 58.
21. AbouYabis AN, Shenoy PJ, Sinha R, et al. A systematic review and meta-analysis of front-line anthracycline-based chemotherapy regimens for peripheral T-cell lymphoma. ISRN Hematol 2011; 2011: 623924.
22. Schmitz N, Trumper L, Ziepert M, et al. Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non- Hodgkin Lymphoma Study Group. Blood 2010;116:3418-3425.
23. Niitsu N, Hayama M, Yoshino T, et al. Multicentre phase II study of the CyclOBEAP regimen for patients with peripheral T-cell lymphoma with analysis of biomarkers. Br J Haematol 2010;153:582-588.
24. Stewart M, Talks K, Leek R, et al. Expression of angiogenic factors and hypoxia inducible factors HIF 1, HIF 2 and CA IX in non-Hodgkin's lymphoma. Histopathology 2002;40:253-260. (Pubitemid 34227116)
25. Reimer P, Rudiger T, Geissinger E, et al. Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study. J Clin Oncol 2009;27: 106-113.
26. d'Amore F, Relander T, Lauritzsen GF, et al. Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01.J Clin Oncol 2012;30:3093-3099.
27. Mahadevan D, Unger JM, Spier CM, et al. Phase 2 trial of combined cisplatin, etoposide, gemcitabine, and methylprednisolone (PEGS) in peripheral T-cell non-Hodgkin lymphoma. Cancer 2013;119:371-379.
28. O'C onnor OA, ProB, Pinter-Brown L, et al. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. J Clin Oncol 2011;29:1182-1189.
29. Coiffier C, Pro B, Prince HM, et al. Final results from a pivotal, multicenter, international, open-label, phase 2 study of romidepsin in progressive or relapsed peripheral T-cell lymphoma (PTCL) following prior systemic therapy. Blood 2010;116(Suppl. 1): Abstract 114.
30. Piekarz R, Wright J, Frye R, et al. Final results of a phase 2 NCI multicenter study of romidepsin in patients with relapsed peripheral T-cell lymphoma (PTCL). Blood 2009;114(Suppl. 1): Abstract 1657.
31. Pro B, Advani R, Brice P, et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol 2012;30:2190-2196.
32. Fanale MA, Shustov AR, Forero-Torres A, et al. Brentuximab vedotin administered concurrently with multi-agent chemotherapy as frontline treatment of ALCL and other CD30-positive mature T-cell and NK-cell lymphomas. Blood 2012;120(Suppl. 1): Abstract 60.
33. A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) alternating with pralatrexate (P) as front line therapy for patients with stage II, III and IV peripheral T-cell non-Hodgkin lymphoma (NCT01336933). Available from: www.ClinicalTrials.gov
34. A study of escalating doses of romidepsin in association with CHOP in the treatment of peripheral T-cell lymphomas (NCT01280526). Available from: www.ClinicalTrials.gov
35. Brentuximab vedotin and bendamustine for the treatment of Hodgkin lymphoma and anaplastic large cell lymphoma (ALCL) (NCT01657331). Available from: www.ClinicalTrials.gov
36. Dupuis J, Casasnovas RO, Morschhauser F, et al. Early results of a phase Ib/II dose-escalation trial of romidepsin in association with CHOP in patients with peripheral T-cell lymphomas (PTCL).Blood 2011;118(Suppl. 1): Abstract 2673.
37. Study of pralatrexate versus observation following CHOP-based chemotherapy in previously undiagnosed peripheral T-cell lymphoma patients (NCT01420679). Available from: www.ClinicalTrials.gov